Press

Bright Minds Biosciences Announces Non-Brokered Private Placement

Nov 28 • 4 min read

Bright Minds Biosciences Inc. (CSE:DRUG | NASDAQ:DRUG) is pleased to announce a non-brokered private placement of (i) pre-funded warrants of the Company at a price of $1.249 per PFW, and (ii) units of the Company at a price of $1.25 per Unit.The aggregate minimum gross proceeds of the Unit Offering and the PFW Offering, on…

Field Trip Health & Wellness Ltd. Announces Updated Time for Fiscal Second Quarter 2023 Financial Results and Conference Call

Nov 28 • 2 min read

Field Trip Health & Wellness Ltd. (TSXV: FTHW), a global leader in the delivery of psychedelic therapies, announced today that it now plans to release financial results for its fiscal 2023 second quarter for the three-month period ended September 30, 2022, after market close on Tuesday, November 29, 2022. The Company will conduct a conference…

Albert Labs Announces Private Placement

Nov 27 • 3 min read

Albert Labs International Corp. [CSE: ABRT | FSE: VB50], a biopharmaceutical drug discovery company focused on gaining regulatory approval for active compounds to treat various mental health conditions, has announced a non-brokered private placement for gross proceeds of up to $3,000,000 (the “Offering”), with the first tranche raised at a price of CAD $0.08 per…

Revive Therapeutics Announces FDA Recommendation for Type C Meeting to Discuss Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19

Nov 27 • 3 min read

Revive Therapeutics Ltd. (OTCQB: RVVTF | CSE: RVV | FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announced today that the U.S. Food & Drug Administration (“FDA”) has responded that a Type C meeting would be recommended, which the Company will request, to…

Clearmind Announces Initiation of CMND-100 Manufacturing Program to Address its Upcoming Clinical Trial

Nov 27 • 2 min read

Clearmind Medicine Inc. (Nasdaq: CMND | CSE: CMND | FSE: CWY), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major undertreated health problems, today announced the initiation of clinical batches of production of its novel psychedelic-derived drug candidate, the MEAI- based molecule- CMND-100. The produced batches will be used…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435